Over the past ten years, the global biopharmaceutical market has remarkably grown, with ten over the top twenty worldwide high performance medical treatment sales being biologics. Thus, biotech R&D (research and development) sector is becoming a key leading branch, with expanding revenues. Biotechnology offers considerable advantages compared to traditional therapeutic approaches, such as reducing side effects, specific treatments, higher patient compliance and therefore more effective treatments leading to lower healthcare costs. Within this sector, smart nanotechnology and colloidal self-assembling systems represent pivotal tools able to modulate the delivery of therapeutics. A comprehensive understanding of the processes involved in the self-assembly of the colloidal structures discussed therein is essential for the development of relevant biomedical applications.

In this review we report the most promising and best performing platforms for specific classes of bioactive molecules and related target, spanning from siRNAs, gene/plasmids, proteins/growth factors, small synthetic therapeutics and bioimaging probes.

在过去的十年中，全球生物制药市场显着增长，全球排名前二十位的高性能药物销售中有十个是生物制剂。因此，随着收入的增长，生物技术研发（研究与开发）部门正成为关键的领先分支。与传统的治疗方法相比，生物技术具有可观的优势，例如减少副作用，特定治疗，更高的患者依从性，因此更有效的治疗可降低医疗成本。在这一领域，智能纳米技术和胶体自组装系统代表了能够调节治疗药物交付的关键工具。

在这篇综述中，我们报告了针对特定类别的生物活性分子和相关靶标的最有前途和最佳性能的平台，涵盖了siRNA，基因/质粒，蛋白质/生长因子，小型合成疗法和生物成像探针。